Evaluation of the efficacy of defroxamine- deferiprone on cardiac function in patients with thalassemia major
Phase 3
- Conditions
- Thalassemia major.Beta thalassemia major
- Registration Number
- IRCT2014070512765N4
- Lead Sponsor
- Golestan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Patients were treated with iron chelators Subcutaneous Deferoxamine with a doseof 30-50 mg/kg for 5 nights a week for 3 years before starting the study. Exclusion criteria: gastrointestinal complications; failure to cooperate in the control tests (ALT, CBC); becoming tired of the traffic for controlling consumption of deferiprone
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eft Venticular Ejection Fraction. Timepoint: It is messured for 3 years at the end of each year. Method of measurement: Echocardiography.;Srum ferritin. Timepoint: It is messured for 3 years at the end of each year. Method of measurement: Determining the level of serum ferritin by related test.
- Secondary Outcome Measures
Name Time Method